Replimune Group Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing oncolytic immunotherapies for cancer treatment. Its proprietary product candidates harness oncolytic viruses to selectively replicate in and destroy tumor cells while activating the patient's immune system against cancer. The lead candidate, RP1, is a modified herpes simplex virus type 1 (HSV-1) engineered to express GALV-GP R(-) and human GM-CSF, targeting a broad spectrum of solid tumors. Complementing this, RP2 incorporates an anti-CTLA-4 antibody-like protein to counteract immune inhibition, enhancing T-cell responses. RP3 further advances this platform by expressing additional immune-activating proteins to stimulate T cells more potently. Replimune Group Inc. operates within the oncology sector, focusing on innovative immunotherapies that aim to transform cancer care through precise viral mechanisms. Founded in 2015 and headquartered in Woburn, Massachusetts, the company plays a key role in advancing next-generation biologics in the biopharmaceutical market.